Request Demo
Last update 07 Aug 2025
TQB-2825
Last update 07 Aug 2025
Overview
Basic Info
Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms TQB 2825, TQB-2825, TQB2825 |
Target |
Action inhibitors, stimulants |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
6
Clinical Trials associated with TQB-2825NCT06829771
Phase Ib/II Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
CTR20250154
TQB2825注射液联合免疫化疗在弥漫大B细胞淋巴瘤受试者中的Ib/II期临床试验
[Translation] Phase Ib/II clinical trial of TQB2825 injection combined with immunochemotherapy in subjects with diffuse large B-cell lymphoma
NCT06854445
Phase II Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
100 Clinical Results associated with TQB-2825
Login to view more data
100 Translational Medicine associated with TQB-2825
Login to view more data
100 Patents (Medical) associated with TQB-2825
Login to view more data
100 Deals associated with TQB-2825
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| ALK positive large B-cell lymphoma | Phase 2 | China | 23 Apr 2025 | |
| Mediastinal large B-cell lymphoma | Phase 2 | China | 23 Apr 2025 | |
| T-cell/histiocyte rich large B-cell lymphoma | Phase 2 | China | 23 Apr 2025 | |
| Diffuse large B-cell lymphoma recurrent | Phase 2 | China | 12 Mar 2025 | |
| Diffuse Large B-Cell Lymphoma | Phase 2 | China | 07 Mar 2025 | |
| CD20 positive Hematologic Neoplasms | Phase 1 | China | 10 Mar 2022 | |
| Follicular Lymphoma | IND Approval | China | 26 Aug 2024 | |
| Mantle-Cell Lymphoma | IND Approval | China | 26 Aug 2024 | |
| Marginal Zone B-Cell Lymphoma | IND Approval | China | 26 Aug 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05489276 (EHA2025) Manual  | Phase 1 | Follicular Lymphoma CD20 Positive | 41 | mitjrmttnf(mwwdkhdizy) = ubsyfdajmj calnvhzlrr (uiwwthtnbd ) View more | Positive | 14 May 2025 | |
TQB2825 50mg | mitjrmttnf(mwwdkhdizy) = rqlqoxfxbg calnvhzlrr (uiwwthtnbd ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free